Banking Recap

Anebulo Pharmaceuticals, Inc. to Be Acquired

This record concerns Anebulo Pharmaceuticals, Inc. (ticker ANEB), a healthcare-sector company, acting as both target and issuer in a going-private transaction structured as a reverse stock split. The deal falls under the M&A product group, and its disclosed value is not stated in the source document.

Jul 23, 2025·SEC EDGAR (SC 13E3)·pending regulatory·going-private reverse stock split

The facts are sourced from an SC 13E3 filing with the SEC via EDGAR, published July 23, 2025. The deal's status is pending regulatory, indicating the going-private process had not yet concluded as of that filing.

Only one financial advisor is disclosed: Houlihan Capital, LLC, which served as financial advisor and fairness opinion provider to the company and is designated lead. The source sentence notes that the fairness opinion of Houlihan Capital, LLC, dated July 15, 2025, was made available for inspection and copying at the company's principal executive offices, indicating the opinion addressed the fairness of the reverse stock split transaction to affected stockholders.

The only legal advisor disclosed is Blank Rome LLP, serving as counsel to the company. The source sentence is a notice/copy line from the filing listing attorneys Leslie Marlow, Esq. and Melissa Palat Murawsky, Esq. of Blank Rome LLP as recipients of filing copies, indicating the firm's role as counsel in the matter.

Beyond classifying the transaction as a going-private reverse stock split, the facts block does not specify the split ratio, the cash-out price for fractional shares, or other mechanical terms of the reverse split.

Several facts are not disclosed in this record. The transaction's dollar value is not stated. No expected closing date is given, and the facts block does not specify the reverse stock split ratio or the treatment of stockholders who would be cashed out as a result of the split.